Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

Alexis Ogdie,¹ Philip Mease,^{2,3} Francois Nantel,⁴ Frederic Lavie,⁵ Mohamed Sharaf,⁶ Emmanouil Rampakakis,^{7,8} Helena Marzo-Ortega,⁹ Laure Gossec¹⁰ ¹Division of Rheumatology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA; ²Rheumatology Research, Providence Swedish Medical Center, Seattle, WA, USA; ⁴Nantel Medsci Consult, Montreal, QC, Canada; ⁵Johnson & Johnson, Issy les Moulineaux, France; ⁶Johnson & Johnson, Dubai, UAE; ⁷Department of Pediatrics, McGill University, Montreal, QC, Canada; ⁹NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; ¹⁰Sorbonne Université and AP-HP, Pitié-Salpêtrière Hospital, Paris, France

Background

Psoriatic arthritis (PsA) disease activity and impact on patients are measured with clinical and patient-reported outcomes (PROs)¹

Minimal clinically important improvement (MCII), the smallest improvement perceived by patients as clinically meaningful², has been defined for multiple PsA outcome measures, mainly using observational data^{3,4}



Guselkumab (GUS), a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved for the treatment of adults with active PsA - GUS demonstrated early, significant, and sustained multi-domain efficacy

- across 3 Phase 3 randomized controlled trial (RCT) populations of PsA patients with variable treatment history⁵⁻⁷
- MCII thresholds for PsA outcomes have not yet been evaluated across lines of treatment or varying levels of disease activity in PsA patients treated with GUS

Objectives


MCII thresholds for efficacy outcomes were determined in subsets of PsA patients, stratified by treatment history and baseline disease activity, utilizing pooled data from 3 Phase 3 RCTs

Results

Baseline characteristics were generally well-balanced across tumor necrosis factor inhibitor (TNFi)-experienced and biologic-naïve cohorts

		TNFi-experienced (N=403)	Biologic-naïve (N=1002)	All (N=1405)		
Demographics						
ÅÅ	Age, yrs	49.4 (11.7)	46.2 (11.7)	47.1 (11.8)		
	Male	50%	52%	51%		
	White/Asian	86%/14%	97%/3%	96%/4%		
	Weight, kg	86.0 (19.4)	84.8 (19.4)	85.2 (19.4)		
Characteristics						
È 🥺	cDAPSA (0-154)	43.7 (19.8)	44.4 (19.9)	44.2 (19.8)		
	ModDA: >13 and ≤27	16%	15%	15%		
	HDA: >27	84%	84%	84%		
	PASDAS (0-10)	6.4 (1.0)	6.5 (1.1)	6.5 (1.1)		
	ModDA: >3.2 and ≤5.4	16%	16%	16%		
	HDA: >5.4	84%	84%	84%		
	PtGA-Arthritis (0-100 VAS)	65.0 (17.9)	63.6 (19.7)	64.0 (19.2)		
	PtGA-Psoriasis (0-100 VAS)	61.4 (24.1)	60.5 (24.3)	60.8 (24.2)		
_	Patient Pain (0-100 VAS)*	63.7 (18.7)	60.8 (19.9)	61.6 (19.6)		
<u>{</u> لاً	HAQ-DI (0-3)**	1.3 (0.6)	1.2 (0.6)	1.3 (0.6)		
-	FACIT-Fatigue (0-52)	29.0 (10.9)	30.1 (9.9)	29.8 (10.2)		
Medication u	ise at baseline					
A.	csDMARDs	66%	67%	67%		
	Methotrexate	58%	58%	58%		

Nominal *p<0.05; **p<0.01 for TNFi-experienced vs. biologic-naïve based on a 2-sample t-test for continuous variables. Data shown are mean (SD), unless otherwise indicated. cDAPSA=Clinical Disease Activity for PsA, csDMARD=Conventional synthetic disease-modifying antirheumatic drug, FACIT=Functional Assessment of Chronic Illness Therapy, HAQ-DI=Health assessment questionnaire-disability index, HDA=High disease activity, ModDA=Moderate disease activity, PASDAS=PsA Disease Activity Score, PtGA=Patient Global Assessment, SD=Standard deviation, TNFi=Tumor necrosis factor inhibitor, **VAS**=Visual analog scale, **yrs**=Years




Outcome


cDAPSA (0-154)				
PASDAS (0-10)				
PtGA Arthritis (0-100)				
PtGA Psoriasis (0-100)				
Patient Pain (0-100)				
HAQ-DI (0-3)				
FACIT-Fatigue (0-52)				

treatment history





Consulting fees: AbbVie, Amgen, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Sandoz, and UCB. Previously presented at American College of Rheumatology (ACR) Convergence; Washington, D.C., USA; November 14–19, 2024.



Odds ratio (OR; 95% confidence interval [CI]) and nominal p-values comparing GUS vs. PBO are shown as **p<0.001; ****p<0.0001; ****p<0.0001. *First time point assessed common to all 3 RCTs. N represents TNFiexperienced GUS Q8W/PBO and biologic-naive GUS Q8W/PBO patients with baseline scores >MCIL cDAPSA=Clinical Disease Activity for PsA, CI=Confidence interval, GUS=Guselkumab, MCII=Minimal clinically important improvement, OR=Odds ratio, PBO=Placebo, PtGA=Patient Global Assessment, Q8W=Every 8 weeks, RCT=Randomized controlled trial, TNFi=Tumor necrosis factor inhibitor, W=Week

OR (95% CI) and nominal p-values comparing GUS vs. PBO are shown as ***p<0.001; ****p<0.0001. *First time point assessed common to all 3 RCTs. N represents TNFi-experienced GUS Q8W/PBO and biologicnaïve GUS Q8W/PBO patients with baseline scores >MCII. CI=Confidence interval, GUS=Guselkumab, MCII=Minimal clinically important improvement, OR=Odds ratio, PASDAS=PsA Disease Activity Score; PBO=Placebo, PtGA=Patient Global Assessment, Q8W=Every 8 weeks, RCT=Randomized controlled trials, TNFi=Tumor necrosis factor inhibitor, W=Week





Patients receiving GUS every 8 weeks (Q8W) across disease domains when compared with



Despite greater cDAPSA thresholds, patients with HDA at baseline remained more likely to achieve early (W8) MCII with GUS Q8W than

sure / disease activity at baseline	Estimated MCII	Reference MCII	
	8.7		
ith ModDA	4.1	3.25 ³ -5.7 ⁴	
ith HDA	9.1		
	0.8		
ith ModDA	0.7	0.8 ^{a,8-10}	
ith HDA	0.8		

cDAPSA HDA: >27; PASDAS ModDA: >3.2 and ≤5.4; PASDAS HDA: >5.4. N represents GUS Q8W/PBO with baseline scores >MCII. cDAPSA=Clinical Disease Activity for PsA, CI=Confidence interval, GUS=Guselkumab, HDA=High disease activity, MCII=Minimal clinically important improvement, ModDA=Moderate disease activity, ns=Not significant, OR=Odds ratio, PASDAS=PsA Disease Activity Score, PBO=Placebo, Q8W=Every 8 weeks, RCT=Randomized controlled trial, W=Week